What the FDA labels say about taking them together
Docetaxel and ritonavir
Docetaxel's FDA label of July 15, 2025 names ritonavir in its drug interactions section; the ritonavir label PlainMeds reads does not name docetaxel. The docetaxel label: “Protease inhibitors, particularly ritonavir, may increase the exposure of docetaxel.”
Check it at the source: the docetaxel FDA label on DailyMed (effective July 15, 2025, Avyxa Pharma, LLC); the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.).
What does the docetaxel label say about ritonavir?
Docetaxel label, drug interactionsProtease inhibitors, particularly ritonavir, may increase the exposure of docetaxel.
Source: FDA drug label (DOCIVYX), Avyxa Pharma, LLC, effective July 15, 2025 (SPL set 4763744e-360e-4d37-be05-cce4114548cd), via openFDA; the full label on DailyMed
What does the ritonavir label say about docetaxel?
Ritonavir's label (effective July 23, 2026) does not name docetaxel in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Docetaxel | Ritonavir | |
|---|---|---|
| Labeled for | Breast cancer, Lung cancer, Prostate cancer | HIV |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $0.607 per tablet 100 mg tablet |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once